Pfizer, BioNTech prep flu-COVID mRNA combo shot for phase 3, reprising Moderna race after seeing early data

The race is on—again. Having already gone up against Moderna in COVID-19 and influenza, Pfizer and BioNTech have now followed their recurring rival in reporting early-phase data on an mRNA combination vaccine against both pathogens—and in outlining plans to start a pivotal trial.